BioSpace News Archive

Moleculin Biotech, Inc. today announced that positive preclinical data regarding the Company’s next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting.

Kerecis announced that, over the past year, 63 million more Americans became eligible for insurance coverage for the company’s fish-skin treatments, an increase of more than 70%.

The human brain has a sweet tooth, burning through nearly one quarter of the body’s sugar energy, or glucose, each day.

The annual general meeting in Orexo AB on 18 April 2023 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be eight with no deputy board members.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced the initial Phase 1 results from the GLIMMER-01 trial of its lead EAGLE oncology platform program, E-602, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter before market open on Tuesday, May 2, 2023.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens.

InflaRx N.V. announced that, in connection with its previously announced completion of its underwritten public offering of 9,411,765 ordinary shares, the underwriters have fully exercised their option to purchase an additional 1,411,764 ordinary shares at a public offering price of $4.25 per ordinary share.

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023, at 4:30 pm Eastern Time.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.